As part of the rollout of vaping reforms from 2024, from 1 July 2025, the Therapeutic Goods Administration (TGA) is implementing strengthened standards for all therapeutic vaping goods for smoking cessation and nicotine dependence. These include stricter requirements for ingredients, packaging and labelling. These stronger safety and quality standards are designed to mitigate certain risks associated with the use of therapeutic vapes. Pharmacies can only supply vapes that meet these new standards.
Health professionals can consult the TGA notified vape list to identify therapeutic vaping products that comply with TGA product standards for smoking cessation or managing nicotine dependence. Products that don’t meet the new standards can no longer be prescribed or supplied from 1 July 2025.
For more information see the TGA website https://www.tga.gov.au/news/news/new-standards-nicotine-vaping-products-july-2025.
It is important to remember that vapes are not recommended as the first-line treatment for smoking cessation support. First-line treatments include behavioural intervention such as Quitline, and TGA-approved pharmacotherapies such as nicotine replacement therapy. See Clinical Tools & Guidelines for more information and resources.